33 results about "Corneal wound" patented technology

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

The invention provides a human keratinocyte growth factor -1 structure analogues KGF-1delta 23KGF(40S), an N end of an amino acid sequence of which lacks 23 amino acids, while the 40-bit cysteine point of which is mutated into a nonpolar amino acid. The invention also relates to a production method of the structure analogues, which carries out the fusion expression with a small ubiquitin related modifier gene mature peptide, while a fusion protein and the ubiquitin related modifier gene protease 1 co-express in the prokaryotes. In the process of fermentation expression, the ubiquitin related modifier gene protease 1 can hydrolyze the fusion protein to produce a soluble KGF-1delta 23KGF (40S). The human keratinocyte growth factor structure analogues can facilitate the proliferation of the keratinocyte cells, the growth of the hair follicle cells and inhibit the growth of the fibroblast cells, and has the functions of anti-scar, anti-fibrosis, epidermis healing facilitation and corneal wound reparation, etc.

The invention discloses a sodium hyaluronate eyedrop containing deproteinized calf blood extractive. The components comprise deproteinized calf blood extractive, sodium hyaluronate, pH buffering agent, metal chelating agent, osmotic pressure regulation agent and injection water. The preparation method has the following steps: weighing the sodium hyaluronate, adding the injection water to resolve, and obtaining sodium hyaluronate solution after overnight swelling; fetching the deproteinized calf blood extractive, the pH buffering agent, the metal chelating agent and the osmotic pressure regulation agent, adding the injection water to resolve, mixing with the sodium hyaluronate solution after resolving, and agitating uniformly after supplementing the injection water to full dose; filtering and sterilizing after adjusting the pH of the solution, embedding to single dose packaging containers after being qualified by testing, and sealing and obtaining the product. The eyedrop disclosed by the invention is used for curing corneal wounds and xerophthalmia, can promote the corneal cells to incept and utilize the energy, and improves the recovery rate of the corneal wounds. The preparation method of the eyedrop avoids the stimulus to the surface cells of eyes, and prevents the contamination caused by microorganisms in tears and in air during use and storage.

The invention belongs to the technical field of medicines, and in particular relates to high-fidelity chitosan sodium hyaluronate eye drops and a preparation method thereof. Specifically, the high-fidelity chitosan sodium hyaluronate eye drops are prepared from the following components in percentage by weight: 0.03-0.1 wt% of chitosan, 0.1-0.3 wt% of sodium hyaluronate, 0.5wt% of an isoosmotic adjusting agent, 0.5-1.0 wt% of auxiliary material, 0.01-0.03 wt% of borneol and a pH value regulator, and the balance of water for injection. The addition quantity of the pH value regulator enables the pH value of the composition to be 6.0-9.0. The high-fidelity chitosan sodium hyaluronate eye drops intrinsically have the corrosion inhibition function, and the existing experimental data prove that the high-fidelity chitosan sodium hyaluronate eye drops have the functions of effectively preventing and treating the xerophthalmus and promoting the corneal wound healing.

A nanoglue is formed with one or more bioadhesive polymers, one or more dendrimers, and optionally one or more therapeutic, prophylactic, or diagnostic agents. The bioadhesive polymers and dendrimers are modified with functional groups to permit crosslinking upon one or more stimuli, e.g., ultraviolet irradiation, and form hydrogel in situ at tissue sites. In the repair of corneal wounds, the nanoglue leads to improved rate of healing with less scarring and less inflammation, compared to non-treated cornea or ones treated with sutures. Therapeutic agents can be covalently conjugated to the precursor components and be delivered to specific eye compartments, providing a more efficacious treatment formulation of ocular disorders than delivering drugs in their free forms. Methods of making and using the hydrogel and hydrogel precursor compositions are also provided.

Described herein are methods of enhancing wound healing using silk-derived proteins (SDP), including low molecular weight SDP fragments. Also described are compositions for the treatment of wounds, including corneal wounds, skin wounds, surgical incisions, burns, and skin ulcers, comprising SDP fragments, including low molecular weight SDP fragments.

The present invention relates to pharmaceutical compositions containing lactoferrin, or fragments of it, and their use in the treatment of wounds, particularly corneal wounds. The present invention also provides a pharmaceutical composition comprising an effective amount of a polypeptide or peptidomimetic consisting essentially of the C-lobe of lactoferrin, or functionally active fragments or variants thereof.

The invention belongs to the field of medical devices, and relates to a high-performance renewable corneal material, a preparation method and an application thereof. The preparation method of the corneal material comprises the following steps: harvesting fresh lamellar corneas from animal or human eyeballs under aseptic conditions, and sequentially performing preliminary mild decellularization, elution and removal of decellularization agent, supplementation of glycosaminoglycan for crosslinking, subsequent repeated thorough decellularization, secondary elution and removal of the decellularization agent, preservation with preserving liquid and sterilization. According to the invention, the high-performance renewable corneal material prepared by a repeated decellularization technology and akey technology of synergistic modification with efficient healing-promoting materials has high transparency, good mechanical property, good degradation resistance and biocompatibility and can promotehealing of corneal wounds. The high-performance renewable corneal material is a major breakthrough in corneal material preparation technology. Meanwhile, the process of the present invention is simple, flexible, good in product reproducibility and easy to realize industrial popularization. The renewable corneal material of the present invention can be widely used for treating blinding eye diseasescaused by corneal lesions or corneal injuries.

The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.

The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin β4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin β4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.